300+ investors in your industry, stage, and region Get
Any industry
Big Data
Video Games
Clean Energy
Google
Construction
Hospitality
EdTech
Consumer
Artificial Intelligence
Local
Platforms
Travel
InsurTech
Oil and Gas
Enterprise Software
Retail
Social Impact
Cryptocurrency
SaaS
Film
Restaurants
Payments
Photography
Email
CleanTech
Energy
Marketplace
Fitness
Organic Food
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Education
Mobile
Wellness
Sports
Medical Device
Legal
Biotechnology
Software
Automotive
Renewable Energy
eSports
Crowdfunding
Venture Capital
Fashion
Beauty
Theatre
Social
Infrastructure
Recruiting
LGBT
Cannabis
Climate
Celebrity
Mobile Apps
Wine and Spirits
Web3
Medical
Food and Beverage
Music
Sporting Goods
Publishing
Real Estate
Art
Life Science
Digital Media
Financial Services
FinTech
Manufacturing
Social Media
Finance
Franchise
Mobile Advertising
Non Profit
Android
Internet
Biotech
Enterprise
Community
Media (Entertainment)
Sustainability
Transportation
Proptech
Impact
Hardware
Any country
Afghanistan
United Kingdom
Hong Kong
Thailand
United Arab Emirates
Greece
Benin
Croatia
Japan
South Korea
Burkina Faso
Africa
Brazil
Singapore
Oceania
LATAM
Gibraltar
Egypt
Kyrgyzstan
Zambia
Zimbabwe
Sweden
Taiwan
Norway
Tajikistan
Tunisia
Liberia
Malawi
Mexico
Nigeria
Russian Federation
Togo
Nepal
Guinea
Haiti
Iran
Isle of Man
Lesotho
Madagascar
Pakistan
Romania
Oman
Andorra
Poland
Puerto Rico
Guernsey
Cameroon
Sudan
Colombia
China
Armenia
Costa Rica
Czech Republic
Kuwait
Kenya
Marshall Islands
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Morocco
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Turkey
Uganda
Uruguay
Botswana
Moldova
Seychelles
Paraguay
Canada
South Africa
France
Ireland
Georgia
Denmark
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Rwanda
Sierra Leone
Senegal
El Salvador
Tanzania
India
Germany
United States
Indonesia
Middle East
Bermuda
Portugal
Dominican Republic
Asia
Qatar
Albania
Argentina
Bangladesh
Spain
Barbados
Belgium
Angola
Europe
Austria
Ethiopia
Cyprus
Jordan
Azerbaijan
Bulgaria
Ecuador
Estonia
Bolivia
Belize
Faroe Islands
Jersey
Algeria
Bahrain
Italy
Finland
Belarus
Bahamas
Hungary
Grenada
Israel
Lithuania
Liechtenstein
Lebanon
Honduras
Iceland
Mongolia
Peru
Slovenia
San Marino
Ukraine
Cambodia
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database

NT Investments

VC Fund

NT Investments is an investment firm.

Total investments:
2
Last investment:
Lead investor:
50%

Last updated:

Industries NT Investments invests in

GeneticsHealth CareBiotechnologyHealth Diagnostics

Stages NT Investments invests in

Series BSeries C

Countries NT Investments invests in

United States

Investment Focus

Industry

  • Genetics 1 (50%)
  • Health Care 1 (50%)
  • Biotechnology 1 (50%)
  • Health Diagnostics 1 (50%)

Stage

  • Series B 1 (50%)
  • Series C 1 (50%)

Investments

CompanyDescriptionRoundLinks
Geneoscopy Geneoscopy
Geneoscopy is a non-invasive colorectal cancer diagnostic powered by advanced research in computational biology. The company is determined to replace every patient’s least favorite screen: the colonoscopy. Currently there is no test with high enough specificity and sensitivity to allow patients an alternative to the unpleasant, invasivecolonoscopy. Geneoscopy is changing that.It has developed a novel methodology to reliably and consistently extract human RNA transcripts from stool samples and detect changes in gene expression. This provides Geneoscopy a platform to harness the power of RNA to detect, prevent, and guide treatment for gastrointestinal disease. Geneoscopy is currently developing a diagnostic test for the prevention of colorectal cancer and is conducting research on other applications of its technology for tangential indications. $105M / Series C / Jan 08, 2025
Geneoscopy Geneoscopy
Geneoscopy is a non-invasive colorectal cancer diagnostic powered by advanced research in computational biology. The company is determined to replace every patient’s least favorite screen: the colonoscopy. Currently there is no test with high enough specificity and sensitivity to allow patients an alternative to the unpleasant, invasivecolonoscopy. Geneoscopy is changing that.It has developed a novel methodology to reliably and consistently extract human RNA transcripts from stool samples and detect changes in gene expression. This provides Geneoscopy a platform to harness the power of RNA to detect, prevent, and guide treatment for gastrointestinal disease. Geneoscopy is currently developing a diagnostic test for the prevention of colorectal cancer and is conducting research on other applications of its technology for tangential indications. $105M / Series B / Nov 16, 2021

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Big Data
Video Games
Clean Energy
Google
Construction
Hospitality
EdTech
Consumer
Artificial Intelligence
Local
Platforms
Travel
InsurTech
Oil and Gas
Enterprise Software
Retail
Social Impact
Cryptocurrency
SaaS
Film
Restaurants
Payments
Photography
Email
CleanTech
Energy
Marketplace
Fitness
Organic Food
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Education
Mobile
Wellness
Sports
Medical Device
Legal
Biotechnology
Software
Automotive
Renewable Energy
eSports
Crowdfunding
Venture Capital
Fashion
Beauty
Theatre
Social
Infrastructure
Recruiting
LGBT
Cannabis
Climate
Celebrity
Mobile Apps
Wine and Spirits
Web3
Medical
Food and Beverage
Music
Sporting Goods
Publishing
Real Estate
Art
Life Science
Digital Media
Financial Services
FinTech
Manufacturing
Social Media
Finance
Franchise
Mobile Advertising
Non Profit
Android
Internet
Biotech
Enterprise
Community
Media (Entertainment)
Sustainability
Transportation
Proptech
Impact
Hardware
Any country
Afghanistan
United Kingdom
Hong Kong
Thailand
United Arab Emirates
Greece
Benin
Croatia
Japan
South Korea
Burkina Faso
Africa
Brazil
Singapore
Oceania
LATAM
Gibraltar
Egypt
Kyrgyzstan
Zambia
Zimbabwe
Sweden
Taiwan
Norway
Tajikistan
Tunisia
Liberia
Malawi
Mexico
Nigeria
Russian Federation
Togo
Nepal
Guinea
Haiti
Iran
Isle of Man
Lesotho
Madagascar
Pakistan
Romania
Oman
Andorra
Poland
Puerto Rico
Guernsey
Cameroon
Sudan
Colombia
China
Armenia
Costa Rica
Czech Republic
Kuwait
Kenya
Marshall Islands
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Morocco
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Turkey
Uganda
Uruguay
Botswana
Moldova
Seychelles
Paraguay
Canada
South Africa
France
Ireland
Georgia
Denmark
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Rwanda
Sierra Leone
Senegal
El Salvador
Tanzania
India
Germany
United States
Indonesia
Middle East
Bermuda
Portugal
Dominican Republic
Asia
Qatar
Albania
Argentina
Bangladesh
Spain
Barbados
Belgium
Angola
Europe
Austria
Ethiopia
Cyprus
Jordan
Azerbaijan
Bulgaria
Ecuador
Estonia
Bolivia
Belize
Faroe Islands
Jersey
Algeria
Bahrain
Italy
Finland
Belarus
Bahamas
Hungary
Grenada
Israel
Lithuania
Liechtenstein
Lebanon
Honduras
Iceland
Mongolia
Peru
Slovenia
San Marino
Ukraine
Cambodia
Chile
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does NT Investments invest in?

NT Investments invests primarily in Genetics, Health Care and Biotechnology startups, most often at Series B and Series C stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

When did NT Investments last invest?

The most recent investment recorded for NT Investments closed in Jan 2025. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
NT Investments Find emails